Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Charles River 3Q10 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Charles River 3Q10

RMS segment sales were $159.3 million in the quarter (-3%) and PCS segment sales were down 13% to $116.8 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River 3Q10

3Q Revenues: $276.1 million (-7%)

3Q Loss: $25.2 million (earnings were $37.0 million in 3Q09)

YTD Revenues: $865.5 million (-5%)

YTD Earnings: $5.9 million (earnings were $95.5 million YTD09)

Comments: RMS segment sales were $159.3 million in the quarter (-3%) and PCS segment sales were down 13% to $116.8 million. In response to the continuing decline in demand for services, the company is reducing its headcount by approximately 4%, reducing discretionary spending, closing a leased satellite PCS facility in Laval, Quebec and consolidating its Discovery and Imaging Services (DIS) operation with its larger facility in NC. These actions are expected to generate annual savings of approximately $40 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters